Triastek

Executive Summary

Triastek is a Chinese pharmaceutical company leveraging its proprietary Melt Extrusion Deposition (MED) 3D printing technology to revolutionize oral drug delivery. The MED platform enables the precise fabrication of complex, multi-layer tablets with tailored drug-release profiles, addressing challenges such as poor solubility, narrow therapeutic windows, and variable pharmacokinetics. By combining 3D printing with advanced formulation science, Triastek offers a versatile solution for developing smarter oral dosage forms, particularly for drugs in gastrointestinal, central nervous system, and cardiovascular diseases. The company's technology has the potential to improve patient compliance, reduce side effects, and enable personalized medicine. Founded in 2015 and based in Nanjing, Triastek has progressed to Phase 2 clinical development and is positioned as a pioneer in the emerging field of 3D-printed pharmaceuticals. Triastek has advanced its lead candidate, T19, through Phase 1 studies and into Phase 2 trials for inflammatory bowel disease, demonstrating the platform's ability to achieve targeted colonic release. The company is also exploring applications in other therapeutic areas, including CNS and cardiovascular indications. With a growing intellectual property portfolio and a scalable manufacturing approach, Triastek aims to partner with global pharmaceutical companies to co-develop products and license its technology. The successful completion of ongoing Phase 2 trials and potential strategic partnerships represent key milestones that could validate the MED platform and drive company valuation. As the regulatory landscape for 3D-printed drugs evolves, Triastek is well-positioned to capitalize on first-mover advantages in precision oral drug delivery.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Top-line Data for T19 in IBD70% success
• H2 2026Strategic Partnership or Licensing Deal with Major Pharma60% success
• Q2 2027FDA IND Clearance for New Candidate in Cardiovascular Indication80% success